Advertisement
Advertisement
OTLK
Outlook Therapeutics, Inc. Common Stock
0.43
USDSponsored
+0.04
+10.51%
Feb 06, 15:58 UTC -5
Closed
After-Market
0.42
-0.01
-1.62%
OTLK Earnings Reports
Positive Surprise Ratio
OTLK beat 18 of 35 last estimates.
51%
Next Report
In 4 Days
Date of Next Report
Feb 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$5.13M
/-$0.18
Implied change from Q4 25 (Revenue/ EPS)
-5671.20%
/-5.26%
Implied change from Q1 25 (Revenue/ EPS)
--
/-125.00%
Outlook Therapeutics, Inc. Common Stock earnings per share and revenue
On Dec 19, 2025, OTLK reported earnings of -0.19 USD per share (EPS) for Q4 25, beating the estimate of -0.25 USD, resulting in a 26.47% surprise. Revenue reached -92000, compared to an expected 5.97 million, with a -101.54% difference. The market reacted with a -2.90% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 5.13 million USD, implying an decrease of -5.26% EPS, and decrease of -5671.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Outlook Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Outlook Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 26.47%, and revenue of $-92.00K, -101.54% below expectations.
How did the market react to Outlook Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -2.9%, changed from $2.07 before the earnings release to $2.01 the day after.
When is Outlook Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Outlook Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Outlook Therapeutics, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $5.13M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement